Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
about
Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulationModeling congenital disease and inborn errors of development in Drosophila melanogasterRAS diseases in childrenGermline mutations in HRAS proto-oncogene cause Costello syndromePTPN11 (Shp2) mutations in LEOPARD syndrome have dominant negative, not activating, effectsStructural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation.Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase.Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinomaProtein-tyrosine phosphatases and cancer.A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinomaInhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus.Developmental SHP2 dysfunction underlies cardiac hypertrophy in Noonan syndrome with multiple lentigines.SHP-2 tyrosine phosphatase in human diseases.Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.Ras/MAPK syndromes and childhood hemato-oncological diseases.Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal-regulated kinase/mitogen-activated protein kinase and RhoA signaling pathways.Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRPalpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activationThe Helicobacter pylori virulence factor CagA promotes Erk1/2-mediated Bad phosphorylation in lymphocytes: a mechanism of CagA-inhibited lymphocyte apoptosis.The genomics of lung adenocarcinoma: opportunities for targeted therapies.Diverse biochemical properties of Shp2 mutants. Implications for disease phenotypes.Phosphatase-dependent and -independent functions of Shp2 in neural crest cells underlie LEOPARD syndrome pathogenesis.Congenital Chylothorax as the Initial Presentation of PTPN11-Associated Noonan Syndrome.Enhanced SMAD1 Signaling Contributes to Impairments of Early Development in CFC-iPSCs.Co-occurrence of hypertrophic cardiomyopathy and myeloproliferative disorder in a neonate with Noonan syndrome carrying Thr73Ile mutation in PTPN11.Gene mutations in the Ras pathway and the prognostic implication in Korean patients with juvenile myelomonocytic leukemia.The Roles of Protein Tyrosine Phosphatases in Hepatocellular Carcinoma.Co‐occurrence of hypertrophic cardiomyopathy and juvenile myelomonocytic leukemia in a neonate with Noonan syndrome, leading to premature death.
P2860
Q24540529-A123A982-9E39-48CC-9689-E0C72FB27130Q24655603-B3EBE3AD-4BF1-4AA1-86B9-6CACBA78B727Q26765017-4D367272-21DE-42E1-8E8E-382C834E03A7Q28252058-F3094312-2983-438C-9A94-D3ADD0FA088CQ28272971-7DAA97CA-846C-4074-BDB9-8A40E384EF9FQ28288812-ED4A2C85-B06E-494B-800B-B0C08CE1F0A7Q33556868-A2BEC54C-6ADC-4693-9D4E-EFF2B89418BFQ34627120-D190366B-3080-4931-9B37-1C8C94E6F12EQ35212696-D60DEF1A-9BAC-40D5-A687-30F769AD852AQ35616065-A80455CF-0F7D-4E28-9CCF-EAA9E9A7F5C1Q35943238-35AEC05A-9483-4D55-B8CF-53C7B98B25A5Q36430193-A2E95DAF-B184-4383-82E7-7567A0379EABQ36905741-9C6FC722-976C-44DB-8DDD-0A85CA3F78DAQ36951816-83FA3AA0-0E30-4B36-B91F-6A9EFDB512F2Q37137867-E52B9D5A-58CE-45E5-ADD4-2B60D6E14C58Q37186707-350C5B24-7C4B-47BF-BF0C-68C3A5B57FF0Q37343475-7833BC46-386D-4680-85CC-485A001B4C14Q38068387-9B1A7497-3558-4365-A70D-BF5414D77179Q38605378-C1CF4272-4D6C-4786-AFBD-719EDC9CB3EAQ38631424-DFA5ACFB-4E15-40D5-8935-F18D5F241F1BQ40202131-D8920CC8-6C7F-4AC4-8126-51316D279893Q41891513-0B805919-C8B9-451D-A3EE-B478D90F161AQ42480603-793234A6-8138-415F-BC55-DC0AC9B6ECCFQ42591567-BA904FB5-34CC-4526-874F-2710DB6DB908Q47932289-CA496AED-5C71-4057-8179-AB0F5CC85A8BQ50603572-4B317DB8-2F9B-4EB4-9745-77605E3272F1Q53374749-96F5374E-4FFC-456F-A346-C204501A4EA2Q53407387-33234670-2422-4598-B6D1-267A8C11CED9Q55260605-68592FF5-7A84-4A9E-93C2-6BFCA073159FQ55517431-7FE9282A-3D7F-4246-A009-E6035009608A
P2860
Functional analysis of PTPN11/SHP-2 mutants identified in Noonan syndrome and childhood leukemia.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Functional analysis of PTPN11/ ...... ndrome and childhood leukemia.
@ast
Functional analysis of PTPN11/ ...... ndrome and childhood leukemia.
@en
type
label
Functional analysis of PTPN11/ ...... ndrome and childhood leukemia.
@ast
Functional analysis of PTPN11/ ...... ndrome and childhood leukemia.
@en
prefLabel
Functional analysis of PTPN11/ ...... ndrome and childhood leukemia.
@ast
Functional analysis of PTPN11/ ...... ndrome and childhood leukemia.
@en
P2093
P1476
Functional analysis of PTPN11/ ...... ndrome and childhood leukemia.
@en
P2093
Fumio Takada
Hirofumi Ohashi
Hiroshi Kawame
Hiroshi Tamai
Hotaka Kamasaki
Kenji Kurosawa
Kimio Nishio
Kunihiro Fujii
Masahiro Sakurai
Masue Imaizumi
P2888
P304
P356
10.1007/S10038-005-0239-7
P577
2005-04-15T00:00:00Z